{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:35:50Z","timestamp":1792697750326,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1124\/jpet.106.112755","type":"journal-article","created":{"date-parts":[[2006,10,17]],"date-time":"2006-10-17T08:09:13Z","timestamp":1161072553000},"page":"211-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Concentration-Dependent Mode of Interaction of Angiotensin II Receptor Blockers with Uric Acid Transporter"],"prefix":"10.1016","volume":"320","author":[{"given":"Takashi","family":"Iwanaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoji","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Ogihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikumi","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.106.112755_bib1","doi-asserted-by":"crossref","unstructured":"Alderman MH, Cohen H, Madhavan S, and Kivlighn S (1999) Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34: 144\u2013150.","DOI":"10.1161\/01.HYP.34.1.144"},{"key":"10.1124\/jpet.106.112755_bib2","doi-asserted-by":"crossref","unstructured":"Burnier M (2001) Angiotensin II type 1 receptor blockers. Circulation 103: 904\u2013912.","DOI":"10.1161\/01.CIR.103.6.904"},{"key":"10.1124\/jpet.106.112755_bib3","doi-asserted-by":"crossref","unstructured":"Burnier M, Rutschmann B, Nessberger J, Versaggi J, Shahinfar S, Weaber B, and Brunner HR (1993) Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22: 339\u2013347.","DOI":"10.1161\/01.HYP.22.3.339"},{"key":"10.1124\/jpet.106.112755_bib4","doi-asserted-by":"crossref","unstructured":"Cannon PJ, Stason WB, Demartini FE, Sommers SC, and Laragh JH (1966) Hyperuricemia in primary and renal hypertension. N Engl J Med 275: 457\u2013464.","DOI":"10.1056\/NEJM196609012750902"},{"key":"10.1124\/jpet.106.112755_bib5","doi-asserted-by":"crossref","unstructured":"Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, and Zeldin RK (2001) Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 23: 1166\u20131179.","DOI":"10.1016\/S0149-2918(01)80099-0"},{"key":"10.1124\/jpet.106.112755_bib6","doi-asserted-by":"crossref","unstructured":"Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, et al. (2002) Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature (Lond) 417: 447\u2013452.","DOI":"10.1038\/nature742"},{"key":"10.1124\/jpet.106.112755_bib7","doi-asserted-by":"crossref","unstructured":"Fauvel JP, Velon S, Berra N, Pozet N, Madonna O, Zech P, and Laville M (1996) Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 28: 259\u2013263.","DOI":"10.1097\/00005344-199608000-00012"},{"key":"10.1124\/jpet.106.112755_bib8","unstructured":"Gonzalez-Ortiz M, Mora-Martinez JM, Martinez-Abundis E, and Barcazar-Munoz BR (2000) Effect of valsartan on renal handling of renal handling of uric acid in healthy subjects. J Nephrol 13: 125\u2013127."},{"key":"10.1124\/jpet.106.112755_bib9","doi-asserted-by":"crossref","unstructured":"Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endo H, and Hosoya T (2004) Clinical and molecular analysis of patients with renal hypouricemia in Japan: influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15: 164\u2013173.","DOI":"10.1097\/01.ASN.0000105320.04395.D0"},{"key":"10.1124\/jpet.106.112755_bib10","doi-asserted-by":"crossref","unstructured":"Iwanaga T, Kobayashi D, Hirayama M, Maeda T, and Tamai I (2005) Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos 33: 1791\u20131795.","DOI":"10.1124\/dmd.105.006056"},{"key":"10.1124\/jpet.106.112755_bib11","doi-asserted-by":"crossref","unstructured":"Johnson JR, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle RK, Rodrigues-Iturbe B, Herrera-Acosta J, and Mazzali M (2003) Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41: 1183\u20131190.","DOI":"10.1161\/01.HYP.0000069700.62727.C5"},{"key":"10.1124\/jpet.106.112755_bib12","doi-asserted-by":"crossref","unstructured":"Kimura M, Mitani H, and Isomura Y (2002) Preclinical and clinical profile of valsartan, a selective angiotensin II type-1 receptor blocker. Nippon Yakurigaku Zasshi 120: 353\u2013360.","DOI":"10.1254\/fpj.120.353"},{"key":"10.1124\/jpet.106.112755_bib13","unstructured":"Kondo T, Yoshida K, Yoshimura Y, Motohashi M, and Tanayama S (1996) Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. Arzneimittelforschung 46: 594\u2013600."},{"key":"10.1124\/jpet.106.112755_bib14","unstructured":"Lin KC, Lin HY, and Chou P (2000) The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27: 1501\u20131505."},{"key":"10.1124\/jpet.106.112755_bib15","doi-asserted-by":"crossref","unstructured":"Malmqvist K, Kahan T, and Dahl M (2000) Angiotensin II type 1 (AT1) receptor blockade in hypertensive woman: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens 13: 504\u2013511.","DOI":"10.1016\/S0895-7061(99)00264-2"},{"key":"10.1124\/jpet.106.112755_bib16","doi-asserted-by":"crossref","unstructured":"Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, Watanabe LA, Barragan J, Matadamas N, Mendiola A, et al. (2000) Effects of losartan and candesartan monotherapy and losartan\/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension: Losartan Trial Investigators. Clin Ther 22: 1186\u20131203.","DOI":"10.1016\/S0149-2918(00)83062-3"},{"key":"10.1124\/jpet.106.112755_bib17","doi-asserted-by":"crossref","unstructured":"Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, and Johnson RJ (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101\u20131106.","DOI":"10.1161\/hy1101.092839"},{"key":"10.1124\/jpet.106.112755_bib18","doi-asserted-by":"crossref","unstructured":"Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, and Aristimuno GG (1980) Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 93: 817\u2013821.","DOI":"10.7326\/0003-4819-93-6-817"},{"key":"10.1124\/jpet.106.112755_bib19","doi-asserted-by":"crossref","unstructured":"Nakashima M, Uematsu T, Kosuge K, and Kanamaru M (1992) Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmaol 42: 333\u2013335.","DOI":"10.1007\/BF00266358"},{"key":"10.1124\/jpet.106.112755_bib20","doi-asserted-by":"crossref","unstructured":"Patterson D, Webster J, McInnes G, Brady A, and MacDonald T (2003) The effects of KT3\u2013671, a new angiotensin II (AT1) receptor blocker in mild to moderate hypertension. Br J Clin Pharmacol 56: 513\u2013519.","DOI":"10.1046\/j.1365-2125.2003.01932.x"},{"key":"10.1124\/jpet.106.112755_bib21","doi-asserted-by":"crossref","unstructured":"Price KL, Sautin YY, Long DA, Zhang Li, Miyazaki H, Mu W, Endou H, Johnson RJ (2006) Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 17: 1791\u20131795.","DOI":"10.1681\/ASN.2006030264"},{"key":"10.1124\/jpet.106.112755_bib22","doi-asserted-by":"crossref","unstructured":"Roch-Ramel F, Guisan B, and Diezi J (1997) Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 280: 839\u2013845.","DOI":"10.1016\/S0022-3565(24)36490-0"},{"key":"10.1124\/jpet.106.112755_bib23","doi-asserted-by":"crossref","unstructured":"Schwocho LR and Masonson NH (2001) Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subject. J Clin Pharmacol 41: 515\u2013527.","DOI":"10.1177\/00912700122010393"},{"key":"10.1124\/jpet.106.112755_bib24","unstructured":"Sica DA and Schoolwerth AC (2000) Renal handling of organic anions and cations: excretion of uric acid, in The Kidney (Brenner BM, ed) 6th ed, pp 680\u2013700, Saunders, Philadelphia, PA."},{"key":"10.1124\/jpet.106.112755_bib25","unstructured":"Suzuki S and Yano K (1996) Pharmacokinetic study of candesartan cilexetil, a novel angiotensin II receptor antagonist, in patients with essential hypertension. J Clin Ther Med 12: 2413\u20132428."},{"key":"10.1124\/jpet.106.112755_bib26","doi-asserted-by":"crossref","unstructured":"Tamimi JJ, Salem II, Mahmood Alam S, Zaman Q, and Dham R (2005) Comparative pharmacokinetics of two tablet formulations of losartan: bioequivalence assessment. Biopharm Drug Dispos 26: 205\u2013210.","DOI":"10.1002\/bdd.448"},{"key":"10.1124\/jpet.106.112755_bib27","doi-asserted-by":"crossref","unstructured":"Terasaki T, Deguchi Y, Kasama Y, Pardridge WM, and Tsuji A (1992) Determination of in vivo steady-state unbound drug concentration in the brain interstitial fluid by microdialysis. Int J Pharm 81: 143\u2013152.","DOI":"10.1016\/0378-5173(92)90006-N"},{"key":"10.1124\/jpet.106.112755_bib28","doi-asserted-by":"crossref","unstructured":"Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4: 879\u2013885.","DOI":"10.1248\/bpb1978.4.879"},{"key":"10.1124\/jpet.106.112755_bib29","doi-asserted-by":"crossref","unstructured":"Yu TF and Berger L (1982) Impaired renal function gout: its association with hypertensive vascular disease and intrinsic renal disease. Am J Med 72: 95\u2013100.","DOI":"10.1016\/0002-9343(82)90593-9"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524331222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524331222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.106.112755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:07:26Z","timestamp":1739984846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524331222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0022356524331222"],"URL":"https:\/\/doi.org\/10.1124\/jpet.106.112755","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1088144.541139","asserted-by":"object"}]},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concentration-Dependent Mode of Interaction of Angiotensin II Receptor Blockers with Uric Acid Transporter","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.106.112755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}